Skip to main content
Clinical Trials/NCT05641064
NCT05641064
Completed
Phase 3

Evaluation of Intraoperative Dexmedetomidine Use on Reducing Inflammatory Response Caused by Cardiopulmonary Bypass in Patients Undergoing Surgical Aortic Valve Replacement

University Hospital Dubrava1 site in 1 country60 target enrollmentNovember 22, 2022

Overview

Phase
Phase 3
Intervention
Placebo
Conditions
Systemic Inflammatory Response
Sponsor
University Hospital Dubrava
Enrollment
60
Locations
1
Primary Endpoint
interleukin 6
Status
Completed
Last Updated
last year

Overview

Brief Summary

Aim of this randomized prospective study is to investigate the immunomodulatory effects of dexmedetomidine on outcomes in patients with isolated aortic stenosis after surgical aortic valve replacement.

Detailed Description

Study will investigate effects of two different doses of dexmedetomidine on concentrations of tumor necrosis factor-α and interleukin-6, on inflammatory parameters (C reactive protein and procalcitonin) and inflammatory complications, renal function, postoperative delirium, anaesthetic and analgetic consumption and compare it to control group. It should provide a better understanding of dexmedetomidine effect on decrease of inflammatory response in patients undergoing cardiac surgery. Short-term infusion of dexmedetomidine could reduce inflammatory postoperative complications, contribute to improvement of perioperative renal function and occurrence of postoperative delirium, supporting recovery and shortening hospital stay.

Registry
clinicaltrials.gov
Start Date
November 22, 2022
End Date
September 22, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital Dubrava
Responsible Party
Principal Investigator
Principal Investigator

Zrinka Safaric Oremus

Principal Investigator

University Hospital Dubrava

Eligibility Criteria

Inclusion Criteria

  • isolated aortic stenosis adult patients with written consent

Exclusion Criteria

  • BMI \<30kg/m2
  • 1st, 2nd and 3rd degree AV block
  • bradycardia HR\<50/min upon arrival to operating theatre
  • neurological disorders (Parkinson's disease, Myasthenia gravis, multiple sclerosis, brain tumors in anamnesis)
  • recent use of psychoactive drugs
  • alcohol and illicit drug addiction
  • diabetes type I with complications
  • patients who develop hypotension after initiation of dexmedetomidine infusion requiring vasoconstriction therapy
  • patients receiving corticosteroids in perioperative period
  • patients with known allergy to dexmedetomidine

Arms & Interventions

Saline

Continuous infusion of saline starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery

Intervention: Placebo

Dexmedetomidine 0.5

Continuous infusion of dexmedetomidine in dose 0.5 mcg/kg/min starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery

Intervention: Dexmedetomidine 0.5mcg/kg/h

Dexmedetomidine 1

Continuous infusion of dexmedetomidine in dose 1 mcg/kg/min starting after invasive monitoring placement and before initiation of cardiopulmonary bypass (CPB) until the end of surgery

Intervention: Dexmedetomidine 1 mcg/kg/h

Outcomes

Primary Outcomes

interleukin 6

Time Frame: 24 hours preoperatively up to 12 hours post CPB

Concentration of IL-6 24 hours preoperatively (T0), before CPB initiation (T1), 5 hours post CPB (T2) and 12 hours post CPB (T3)

tumor necrosis factor alpha

Time Frame: 24 hours preoperatively up to 12 hours post CPB

Concentration of TNF-alpha 24 hours preoperatively (T0), before CPB initiation (T1), 5 hours post CPB (T2) and 12 hours post CPB (T3)

Secondary Outcomes

  • Renal function - creatinine(From recruitment date up to 10 days postoperatively)
  • Renal function - urea(From recruitment date up to 10 days postoperatively)
  • Renal function - diuretic consumption(From recruitment date up to 10 days postoperatively)
  • Renal function - GFR(From recruitment date up to 10 days postoperatively)
  • Renal function - diuresis(From recruitment date up to 10 days postoperatively)
  • Postoperative delirium(From recruitment date up to 30 days postoperatively)
  • Inflammatory marker concentration during hospital stay(From recruitment date up to 30 days postoperatively)
  • Infection rate(From recruitment date up to 30 days postoperatively)
  • Analgesic and anesthetic consumption(From recruitment date up to 10 days postoperatively)

Study Sites (1)

Loading locations...

Similar Trials